Methods of Treating Conditions Associated with the S1P1 Receptor

JP2023548474A5Inactive Publication Date: 2024-11-06ARENA PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526166
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-09
Filing Date
2021-11-08
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0009】 皮膚兆候であるアトピー性皮膚炎を有する患者におけるS1Pモジュレーターについての最初の臨床試験が、本明細書において記載される。リンパ球の減少は、エトラシモドのオンターゲット効果である。研究の間、一部の治験担当医は、リンパ球のレベルがCTCAEグレード3の基準を満たしたため、エトラシモドを中止した。このことは試験の課題を示したが、これはまた、エトラシモドでの処置の中断および再開の効果を評価する予想外の機会ももたらした。試験結果の分析は、投与の中断を伴う患者コホートが、中止後に臨床的リバウンド(またはアトピー性皮膚炎の悪化)を、またエトラシモドでの処置の再開後に臨床効果の回復を示したことを明らかにした。さらに、この所見は、当該患者コホートにおける薬力学的所見と一致した。重要なことに、これらの患者の誰も、処置の中断を正当化することになる感染を示さなかった。

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Described herein are methods for treating atopic dermatitis that allow for effective treatment of the disease with a break in the event of certain adverse events. Additionally, described herein are novel methods for treating moderate to severe atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art

Claims

1. For use in a method for treating moderate to severe atopic dermatitis in a patient in need thereof. A pharmaceutical composition comprising etrasimod or a pharma- ceutical acceptable salt thereof, The method further comprising: administering said pharmaceutical composition to a patient in need thereof; (a) identifying a threshold absolute lymphocyte count (ALC) in the patient, where the threshold ALC is less than 500 / mm 3 , or between 0.2×10e9 cells / L and 0.5×10e9 cells / L; or (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; If the ALC level is below a threshold level or if one or more infections are identified, ceasing administration of the pharmaceutical composition for a discontinuation period; and and continuing administration of said pharmaceutical composition for a continuous period after administration has ceased for a discontinuation period. Including, The pharmaceutical composition is administered in an amount equivalent to 1 to 5 mg of etrasimod. Pharmaceutical compositions.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered once a day for a sustained period of time.

3. A pharmaceutical composition described in any one of claims 1 to 2, wherein the pharmaceutical composition is administered in an amount equivalent to 2 mg of etrasimod or an amount equivalent to 3 mg of etrasimod.

4. 4. The pharmaceutical composition of claim 1, wherein the discontinuation period is at least one week or the duration is at least one month.

5. 5. The pharmaceutical composition of claim 1, wherein the patient has been diagnosed with moderate atopic dermatitis and has a vIGA score of 3, or has been diagnosed with severe atopic dermatitis and has a vIGA score of 4.

6. 5. The pharmaceutical composition of claim 1, wherein the patient has atopic dermatitis of 10% or more of the body surface area (BSA).

7. A pharmaceutical composition described in any one of claims 1 to 6, wherein the method comprises the step of (a) identifying a threshold absolute lymphocyte count (ALC) in the patient and further comprises the step of testing circulating blood levels of lymphocytes in the patient.

8. The method of claim 1, further comprising: (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; 7. The pharmaceutical composition of claim 1, further comprising the step of monitoring the patient for infection after the discontinuation period and continuing the cessation of treatment if infection is identified.

9. The method of claim 1, further comprising: (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; 9. The pharmaceutical composition of any one of claims 1 to 6 and 8, wherein the one or more infections are selected from a urinary tract infection, an ear infection, the common cold, diphtheria, E. coli, giardiasis, HIV / AIDS, mononucleosis, influenza, Lyme disease, measles, meningitis, mumps, pneumonia, Salmonella infection, a respiratory infection, shingles, herpes, tuberculosis, viral hepatitis, or COVID-19.